http://ideas.eyeconx.net/story.php?title=bevacizumab-as-first-line-therapy-for-retinopathy-of-prematurity- Bevacizumab (Avastin), an angiogenesis inhibitor, is being used as an alternative therapy for retinopathy of prematurity (ROP) in some children's hospitals for premature babies. Results from a study of this off-label use were reported here at the American Association for Pediatric Ophthalmology and Strabismus 38th Annual Meeting. Helen Mintz-Hittner, MD, from the University of Texas Health Science... Mon, 07 May 2012 15:41:09 EDT en